Azide-Modified Biomolecules for HIV Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral treatments for viral infections, particularly HIV, face challenges such as toxicity, limited efficacy, and the rapid development of drug-resistant strains due to the high genetic variability of HIV, necessitating the need for new and improved therapeutic methods.
Innovation Solution
The use of azide-modified biomolecules, including azide-modified fatty acids, carbohydrates, and isoprenoid lipids, which can be administered to treat viral infections by inhibiting viral infectivity and labeling viral proteins, thereby interfering with the viral life cycle and entry into host cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-viral treatments are used, then viral infections can be treated, but toxicity and serious side effects occur
Solution Approach 1:
The patent modifies the chemical structure of nucleoside analogs by replacing the 3'-hydroxyl group with an azide group, creating a new chemical parameter configuration that maintains anti-viral activity while reducing toxicity. This structural parameter change allows the compound to inhibit reverse transcriptase without causing the severe side effects associated with existing treatments like AZT and d4T
Solution Approach 2:
The invention creates composite molecular structures by combining the nucleoside backbone with an azide functional group, forming a new class of hybrid compounds that exhibit both anti-viral properties and reduced cytotoxicity. These composite structures include compounds like 1-(2'-azido-2'-deoxy-beta-D-erythro-pentofuranosyl)thymine and its derivatives
2Reliability
If existing anti-viral treatments are used, then some viral infections can be controlled, but multidrug resistance develops
Solution Approach 1:
By changing the chemical parameter at the 3' position from hydroxyl to azide, the patent creates compounds with novel mechanisms of action that are not recognized by viral resistance mechanisms developed against existing drugs. This parameter modification allows the azide compounds to maintain efficacy against strains resistant to conventional nucleoside analogs
Solution Approach 2:
The patent creates analog copies of natural nucleosides with modified functional groups, producing compounds that mimic the structure and function of natural substrates while evading viral resistance. The azide-modified compounds serve as deceptive copies that viral polymerases incorporate but then terminate replication, overcoming resistance to standard nucleoside inhibitors
3Productivity
If nucleoside analogs lacking 3'-hydroxyl group are used, then viral DNA replication is terminated, but the treatments are highly toxic
Solution Approach 1:
The patent changes the terminal functional group parameter from 3'-hydroxyl to 3'-azide, maintaining the chain-terminating capability against viral DNA replication while reducing the toxic effects on host cells. The azide group preserves the anti-viral mechanism of blocking phosphodiester bond formation while exhibiting lower cytotoxicity compared to the hydroxyl-containing analogs
Data Source
AI summary
Methods of using azide-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to inhibit infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as human immunodeficiency virus, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. Also, provided are methods of tracking a virus in vivo, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The azide-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome.